cilengitide has been researched along with pyrroles in 2 studies
| Studies (cilengitide) | Trials (cilengitide) | Recent Studies (post-2010) (cilengitide) | Studies (pyrroles) | Trials (pyrroles) | Recent Studies (post-2010) (pyrroles) |
|---|---|---|---|---|---|
| 194 | 29 | 133 | 26,129 | 2,815 | 12,100 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alghisi, GC; Ponsonnet, L; Rüegg, C | 1 |
| Cohen, EE; Fleming, GF; Harris, PJ; Janisch, L; Karovic, S; Karrison, TG; Levine, MR; Maitland, ML; O'Donnell, PH; Polite, BN; Ratain, MJ | 1 |
1 trial(s) available for cilengitide and pyrroles
| Article | Year |
|---|---|
Serum C-Telopeptide Collagen Crosslinks and Plasma Soluble VEGFR2 as Pharmacodynamic Biomarkers in a Trial of Sequentially Administered Sunitinib and Cilengitide.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Biomarkers, Tumor; Collagen Type I; Female; Humans; Indoles; Male; Middle Aged; Neoplasm Staging; Neoplasms; Neovascularization, Pathologic; Peptides; Pyrroles; Snake Venoms; Sunitinib; Vascular Endothelial Growth Factor Receptor-2 | 2015 |
1 other study(ies) available for cilengitide and pyrroles
| Article | Year |
|---|---|
The integrin antagonist cilengitide activates alphaVbeta3, disrupts VE-cadherin localization at cell junctions and enhances permeability in endothelial cells.
Topics: Animals; Antigens, CD; Cadherins; Cell Adhesion; Cells, Cultured; Endothelial Cells; Endothelium, Vascular; Enzyme Induction; Focal Adhesion Protein-Tyrosine Kinases; Humans; Integrin alphaVbeta3; Integrin beta1; Intercellular Junctions; Permeability; Phosphorylation; Pyrimidines; Pyrroles; Snake Venoms; src-Family Kinases | 2009 |